Leading partner in TechnoPhage Clinical Trial

Vector B2B – Drug Development has been elected as the lead partner to manage the TechnoPhage clinical trial on Diabetic Foot Ulcers. TechnoPhage trusted Vector B2B – Drug Development to conduct the TP-102_101/REVERSE study, a Phase I/IIa Double-Blind Randomized Clinical Trial to determine the safety and tolerability of the bacteriophage cocktail TP-102 in subjects with […]